	US 12,251,449 B2
	Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase
Jeffrey Hartgerink, Pearland, TX (US); Andrew G. Sikora, Houston, TX (US); David Leach, Houston, TX (US); Jared M. Newton, Houston, TX (US); and Simon Young, Houston, TX (US)
Assigned to William Marsh Rice University, Houston, TX (US); Baylor College of Medicine, Houston, TX (US); and The Board of Regents of The University of Texas System, Austin, TX (US)
Filed by William Marsh Rice University, Houston, TX (US); Baylor College of Medicine, Houston, TX (US); and The Board of Regents of the University of Texas System, Austin, TX (US)
Filed on Dec. 18, 2020, as Appl. No. 17/127,512.
Claims priority of provisional application 62/950,718, filed on Dec. 19, 2019.
Prior Publication US 2021/0205468 A1, Jul. 8, 2021
Int. Cl. A61K 47/69 (2017.01); A61K 31/7052 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 47/6903 (2017.08) [A61K 31/7052 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)]

10 Claims

1. A peptide comprising a first domain, a second domain, and a third domain; wherein the first and third domain are each X_mand m is 1-3; wherein the first domain is positioned at the N-terminal end of the second domain; wherein the third domain is positioned at the C-terminal end of the second domain; wherein the second domain comprises (SerLeu)₆; and wherein X is an amino acid having a side chain of N6-(1-iminoethyl)-lysine (L-NIL).